Abstract

Transient receptor potential canonical (TRPC) proteins form nonselective cation channels that play physiological roles in a wide variety of cells. Despite growing evidence supporting the therapeutic potential of TRPC6 inhibition in treating pathological cardiac and renal conditions, mechanistic understanding of TRPC6 function and modulation remains obscure. Here we report cryo-EM structures of TRPC6 in both antagonist-bound and agonist-bound states. The structures reveal two novel recognition sites for the small-molecule modulators corroborated by mutagenesis data. The antagonist binds to a cytoplasm-facing pocket formed by S1-S4 and the TRP helix, whereas the agonist wedges at the subunit interface between S6 and the pore helix. Conformational changes upon ligand binding illuminate a mechanistic rationale for understanding TRPC6 modulation. Furthermore, structural and mutagenesis analyses suggest several disease-related mutations enhance channel activity by disrupting interfacial interactions. Our results provide principles of drug action that may facilitate future design of small molecules to ameliorate TRPC6-mediated diseases.

Data availability

The low pass filtered and amplitude modified 3D cryo-EM density maps for TRPC6 in complex with antagonist AM-1473 (accession code: EMD-20954) and agonist AM-0883 (accession code: EMD-20953) have been deposited in the electron microscopy data bank. Atomic coordinates for TRPC6 in complex with antagonist AM-1473 (accession code: 6UZA) and agonist AM-0883 (accession code: 6UZ8) have been deposited in the protein data bank.

The following data sets were generated

Article and author information

Author details

  1. Yonghong Bai

    Molecular Engineering, Amgen Inc, Cambridge, United States
    For correspondence
    ybai80@gmail.com
    Competing interests
    Yonghong Bai, At the time of the study YB was affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare. The author has no other competing interests to declare..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4334-0916
  2. Xinchao Yu

    Molecular Engineering, Amgen Inc, South San Francisco, United States
    For correspondence
    xyu01@amgen.com
    Competing interests
    Xinchao Yu, XY is affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare. The author has no other competing interests to declare..
  3. Hao Chen

    Protein Technologies, Amgen Inc, Cambridge, United States
    Competing interests
    Hao Chen, At the time of the study HC was affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare. The author has no other competing interests to declare..
  4. Daniel Horne

    Medicinal Chemistry, Amgen Inc, Cambridge, United States
    Competing interests
    Daniel Horne, At the time of the study DH was affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare. The author has no other competing interests to declare..
  5. Ryan White

    Medicinal Chemistry, Amgen Inc, Cambridge, United States
    Competing interests
    Ryan White, At the time of the study RW was affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare. The author has no other competing interests to declare..
  6. Xiaosu Wu

    Cardiometabolic Disorders, Amgen Inc, South San Francisco, United States
    Competing interests
    Xiaosu Wu, XW is affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare. The author has no other competing interests to declare..
  7. Paul Lee

    Discovery Technologies, Amgen Inc, Thousand Oaks, United States
    Competing interests
    Paul Lee, At the time of the study PL was affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare. The author has no other competing interests to declare..
  8. Yan Gu

    Protein Technologies, Amgen Inc, Cambridge, United States
    Competing interests
    Yan Gu, At the time of the study YG was affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare. The author has no other competing interests to declare..
  9. Sudipa Ghimire-Rijal

    Molecular Engineering, Amgen Inc, Cambridge, United States
    Competing interests
    Sudipa Ghimire-Rijal, SGR is affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare. The author has no other competing interests to declare..
  10. Daniel C-H Lin

    Cardiometabolic Disorders, Amgen Inc, South San Francisco, United States
    For correspondence
    dclin@amgen.com
    Competing interests
    Daniel C-H Lin, DCHL is affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare. The author has no other competing interests to declare..
  11. Xin Huang

    Molecular Engineering, Amgen Inc, Cambridge, United States
    For correspondence
    hxin@amgen.com
    Competing interests
    Xin Huang, At the time of the study XH was affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare. The author has no other competing interests to declare..

Funding

No external funding was received for this work.

Reviewing Editor

  1. László Csanády, Semmelweis University, Hungary

Version history

  1. Received: November 4, 2019
  2. Accepted: March 7, 2020
  3. Accepted Manuscript published: March 9, 2020 (version 1)
  4. Version of Record published: March 19, 2020 (version 2)

Copyright

© 2020, Bai et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,686
    Page views
  • 838
    Downloads
  • 65
    Citations

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yonghong Bai
  2. Xinchao Yu
  3. Hao Chen
  4. Daniel Horne
  5. Ryan White
  6. Xiaosu Wu
  7. Paul Lee
  8. Yan Gu
  9. Sudipa Ghimire-Rijal
  10. Daniel C-H Lin
  11. Xin Huang
(2020)
Structural basis for pharmacological modulation of the TRPC6 channel
eLife 9:e53311.
https://doi.org/10.7554/eLife.53311

Share this article

https://doi.org/10.7554/eLife.53311

Further reading

    1. Structural Biology and Molecular Biophysics
    Sebastian Jojoa-Cruz, Adrienne E Dubin ... Andrew B Ward
    Research Advance

    The dimeric two-pore OSCA/TMEM63 family has recently been identified as mechanically activated ion channels. Previously, based on the unique features of the structure of OSCA1.2, we postulated the potential involvement of several structural elements in sensing membrane tension (Jojoa-Cruz et al., 2018). Interestingly, while OSCA1, 2, and 3 clades are activated by membrane stretch in cell-attached patches (i.e. they are stretch-activated channels), they differ in their ability to transduce membrane deformation induced by a blunt probe (poking). Here, in an effort to understand the domains contributing to mechanical signal transduction, we used cryo-electron microscopy to solve the structure of Arabidopsis thaliana (At) OSCA3.1, which, unlike AtOSCA1.2, only produced stretch- but not poke-activated currents in our initial characterization (Murthy et al., 2018). Mutagenesis and electrophysiological assessment of conserved and divergent putative mechanosensitive features of OSCA1.2 reveal a selective disruption of the macroscopic currents elicited by poking without considerable effects on stretch-activated currents (SAC). Our results support the involvement of the amphipathic helix and lipid-interacting residues in the membrane fenestration in the response to poking. Our findings position these two structural elements as potential sources of functional diversity within the family.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Tien M Phan, Young C Kim ... Jeetain Mittal
    Research Article

    The heterochromatin protein 1 (HP1) family is a crucial component of heterochromatin with diverse functions in gene regulation, cell cycle control, and cell differentiation. In humans, there are three paralogs, HP1α, HP1β, and HP1γ, which exhibit remarkable similarities in their domain architecture and sequence properties. Nevertheless, these paralogs display distinct behaviors in liquid-liquid phase separation (LLPS), a process linked to heterochromatin formation. Here, we employ a coarse-grained simulation framework to uncover the sequence features responsible for the observed differences in LLPS. We highlight the significance of the net charge and charge patterning along the sequence in governing paralog LLPS propensities. We also show that both highly conserved folded and less-conserved disordered domains contribute to the observed differences. Furthermore, we explore the potential co-localization of different HP1 paralogs in multicomponent assemblies and the impact of DNA on this process. Importantly, our study reveals that DNA can significantly reshape the stability of a minimal condensate formed by HP1 paralogs due to competitive interactions of HP1α with HP1β and HP1γ versus DNA. In conclusion, our work highlights the physicochemical nature of interactions that govern the distinct phase-separation behaviors of HP1 paralogs and provides a molecular framework for understanding their role in chromatin organization.